Deval has worked in the life sciences area developing and commercializing novel technologies. He gained corporate and business development experience through senior management positions in a number of life science companies. He was a founding Research Director at Synteni, which was acquired by Incyte Genomics, where he became Director of Product Development. He also worked with Operon Technologies (acquired by Qiagen), and Genometrix. Deval has represented THP on the boards of AcroMetrix (acquired by Life Technologies), Active Motif, Agena Bioscience (acquired by Mesa Laboratories), Akoya Biosciences (NASDAQ:AKYA), Althea Technologies (acquired by Ajinomoto), AltheaDx, Applied Precision (acquired by GE), Argonaut, Aurora Discovery (acquired by NEXUS Biosystems), Asuragen (acquired by Bio-Techne), Dynex, NEXUS Biosystems (acquired by Brooks Automation), Nimble Therapeutics, Precision NanoSystems (acquired by Danaher), RareCyte, Sage Labs (acquired by Horizon Discovery), and SwitchGear Genomics (acquired by Active Motif). He has been an observer on the boards of Dharmacon (acquired by Fisher Scientific) and Carterra. Deval received a BA from the University of California, Berkeley and a PhD from Stanford University and currently serves on the Stanford Medical School Alumni Board of Governors.
Deval A. Lashkari, Ph.D.